{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:50:00Z","timestamp":1793321400525,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,7,1]]},"DOI":"10.1001\/jamaoncol.2020.1278","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T23:49:32Z","timestamp":1591314572000},"page":"1011","source":"Crossref","is-referenced-by-count":56,"title":["Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant"],"prefix":"10.1001","volume":"6","author":[{"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Myeloma and Lymphoma, University of Texas, MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Woo","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee"},{"name":"Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Khanal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee"},{"name":"Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Litovich","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, Bern University Hospital, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Blood and Marrow Transplant Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosha","family":"Farhadfar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Florida College of Medicine, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar O.","family":"Freytes","sequence":"additional","affiliation":[{"name":"Texas Transplant Institute, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Haverkos","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado Hospital, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Inwards","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rammurti T.","family":"Kamble","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Blood and Marrow Transplantation Program, Mayo Clinic Florida, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Lymphoma, Bone Marrow Transplant and Cellular Therapy Program, UT Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, Blood and Marrow Transplantation Program, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Blood and Marrow Transplantation Program, Mayo Clinic Florida, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d'Oncologia\u2013Hospitalet, Hematology Department, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi200020r1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-017-0487-y","article-title":"Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.","volume":"10","author":"Epperla","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"2","key":"coi200020r2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"coi200020r3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors.","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"coi200020r4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","article-title":"Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis.","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"coi200020r5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research.","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"coi200020r6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"coi200020r7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/bmt.2014.4","article-title":"Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.","volume":"49","author":"Avivi","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"coi200020r8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"coi200020r9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.","volume":"12","author":"Epperla","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"3","key":"coi200020r10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/bmt.2014.269","article-title":"Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.","volume":"50","author":"Hong","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"coi200020r11","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","article-title":"Fludarabine\/busulfan versus fludarabine\/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma.","volume":"22","author":"Kekre","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"coi200020r12","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions.","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"coi200020r13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200020r14","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"coi200020r15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. a long-term clinicopathologic study of 20 Seattle patients.","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"9314","key":"coi200020r16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(02)08272-7","article-title":"Quantification of the completeness of follow-up.","volume":"359","author":"Clark","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"coi200020r17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00985764","article-title":"Score test of homogeneity for survival data.","volume":"1","author":"Commenges","year":"1995","journal-title":"Lifetime Data Anal"},{"issue":"2","key":"coi200020r18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model.","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"coi200020r19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmpb.2010.07.005","article-title":"SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models.","volume":"101","author":"Zhang","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"issue":"4","key":"coi200020r20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1177\/0962280214521348","article-title":"Multiple imputation of covariates by fully conditional specification: accommodating the substantive model.","volume":"24","author":"Bartlett","year":"2015","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"coi200020r24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency.","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann Stat"},{"issue":"20","key":"coi200020r25","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"12","key":"coi200020r26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bmt.2015.174","article-title":"Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.","volume":"50","author":"Yerushalmi","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"coi200020r27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/cncr.v121.7","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"coi200020r28","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/sj.leu.2404886","article-title":"Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan.","volume":"21","author":"Shimoni","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"coi200020r29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma.","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"coi200020r30","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/annonc\/mdx274","article-title":"Reduced-intensity versus reduced-toxicity myeloablative fludarabine\/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire.","volume":"28","author":"Le Bourgeois","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"coi200020r31","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.bbmt.2019.02.002","article-title":"Impact of donor type and melphalan dose on allogeneic transplantation outcomes for patients with lymphoma.","volume":"25","author":"Saini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"coi200020r32","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis.","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi200020r33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"coi200020r21","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"key":"coi200020r22","author":"Liu","year":"2013"},{"key":"coi200020r23","volume-title":"Survival Analysis. State of the Art. NATO Science. Series E: Applied Sciences","author":"Lee","year":"1992"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2766566\/jamaoncology_ghosh_2020_oi_200020_1621979527.95876.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T01:58:08Z","timestamp":1622167088000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2766566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.1278","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}